The management of cirrhosis has evolved at a rapid pace in recent years. During a case-based AASLD symposium on the final day of DDW® 2018, three experts reviewed the most recent developments in diuretic resistant/refractory ascites, recurrent/refractory hepatic encephalopathy and recurrent/refractory variceal bleeding. The panel was co-moderated by Catherine Frenette, MD, FAST, AGAF.
Alcoholic liver disease is getting a new name, alcohol-associated liver disease, or AALD. The disease is also getting new treatment approaches and new attention from researchers, clinicians and industry, according to Gyongyi Szabo, MD, PhD, FAASLD.
The AASLD Clinical Symposium HCV Treatment: Gastroenterologists Role in Eradicating HCV featured a panel of experts who discussed strategies to maximize the number of individuals who are treated for chronic HCV. “Despite recommendations and, in some states, mandates, we are falling behind on HCV screening,” said Robert S. Brown Jr., MD, MPH, AGAF.
In a DDW Daily News video exclusive, DDW Council Chair Grace H. Elta, MD, AGAF, FASGE, discusses four notable abstracts from DDW 2018 in Washington, D.C. Dr. Elta highlights one abstract from each of the four DDW-sponsoring societies.
Although antiviral therapy has led to a cure rate of more than 90 percent of hepatitis C virus (HCV) cases, David E. Bernstein, MD, FAASLD, thinks more can be done to increase the cure rate. In this DDW Daily News video exclusive, Dr. Bernstein discusses several obstacles preventing patients’ access to curative therapies. He also addresses the benefits of HCV therapy and whether it’s possible to eradicate HCV and achieve 100 percent cure rate.
Patrick S. Kamath, MD, DM, MBBS, will define acute-on-chronic liver failure and review its history and scope during Monday’s AASLD State-of-the-Art Lecture Acute on Chronic Liver Failure: Pathophysiology and Therapeutic Approach.
Kathleen E. Corey, MD, MPH, MMSc, will deliver “Challenges in Screening for NAFLD (Including At-Risk Populations)” during Clinical Challenges in Adult and Pediatric Non-Alcoholic Fatty Liver Disease on Monday.
During Sunday’s AASLD State-of-the-Art Lecture Evolving Management of Cholestatic Liver Diseases, Cynthia Levy, MD, FAASLD, will discuss the treatment of primary biliary cholangitis and primary sclerosing cholangitis, the two most common causes of chronic cholestatic liver disease in adults.
AASLD will feature the most innovative research in its two plenary sessions at DDW®, according to AASLD President Ronald J. Sokol, MD, FAASLD. The Basic Science Plenary Session will be held Sunday morning and the Clinical Science Plenary Session will be held Monday morning. Each will offer something for all AASLD members and DDW attendees.
Elizabeth (Lizzie) Aby, MD, shares her favorite aspects of DDW® and digestive disease research, which speaker she would most like to have coffee with, and what she plans to do after the meeting when she returns home to Los Angeles, CA.
